INTRODUCTION {#s1}
============

Testicular cancer (TC) is an malignancy, accounting for 1%--2% of all tumors among men worldwide \[[@R1]\], and affects primarily young men in the age group 15--44 years. The incidence of TC is increasing worldwide and has steeply increased in the past 40 years in almost all Western countries \[[@R2]--[@R4]\]. Clinical studies reported that 95% of all TCs are testicular germ cell tumors (TGCT), with an approximately equal division between seminomas and non-seminomas, and epidemiological studies have suggested that environmental factors, including endocrine disrupting agents, which act as either weak estrogen agonists or androgen antagonists, are primarily responsible for the increased incidence of TC \[[@R5], [@R6]\].

The *AR* gene, located on Xq11-12, has 8 exons and 7 introns, and in exon 1, this gene contains two important polymorphic trinucleotide repeats of polyglutamine and polyglycine tracts \[[@R7], [@R8]\], which are encoded by a (CAG) ~n~CAA stretch, as well as a (GGT)~3~GGG(GGT)~2~(GGC)~n~ repeat, and these repeats are designated CAG and GGN repeats, respectively \[[@R9]\]. The extreme variability of the number of these repeats determines the different lengths of the polyglutamine and polyglycine segments in the N-terminal transactivation domain of the *AR* \[[@R10]\]. In men, the number of CAG repeats can vary from 8 to 37, with an average of 20--22, depending on the ethnic origin. Africans and Asians have a lower number of repeats than Caucasians and a reduced risk of TGCT \[[@R10]\]. Changes in the length of the CAG polymorphic trinucleotide repeat in the *AR* gene may lead to the altered transactivation of the *AR* gene and have been implicated to play a role in the pathogenesis of several forms of endocrine cancer and certain reproductive disorders \[[@R11]\]. Subjects with reproductive disorders that are associated with a relative deficiency in androgen function have an increased risk of TC \[[@R12], [@R13]\]. In the past decade, some studies have attempted to evaluate the association between CAG and GGN repeat number and the risk of TC \[[@R6], [@R9], [@R10], [@R12]--[@R15]\]; however, the results appear contradictory because of differences in the sources of the study participants and inconsistencies in the inclusion criteria in case and control subjects among the studies \[[@R9], [@R16]\]. To the best of our knowledge, to date, no meta-analysis has analyzed the results of all the studies that evaluated this association. Therefore, this meta-analysis was conducted to investigate the association between CAG and GGN repeat polymorphisms and the risk of TC, as well as the genetic heterogeneity across different control sources and study designs. Herein, seven reports involving 3255 TC cases and 2804 controls were identified according to the inclusion criteria for the pooled analysis.

RESULTS {#s2}
=======

Study characteristics {#s2_1}
---------------------

Because not all of the studies evaluated provided specific distributions of *AR* CAG or GGN repeat counts, we used a CAG repeat length of 21--25 as reference to evaluate dichotomous comparisons (\< 21 CAG repeats *vs.* the reference, \> 25 CAG repeats *vs.* the reference, and \< 21 + \> 25 CAG repeats *vs.* the reference). Similarly, the GGN genotype of ≤ 23 repeats was used as reference to assess the association between \> 23 repeats and the risk of TC. Through literature search and selection based on the inclusion criteria, 7 articles published between 2002 and 2015 were identified after reviewing potentially relevant articles (Figure [1](#F1){ref-type="fig"}). The characteristics of the enrolled studies are summarized in Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}.

![Flow diagram of the study selection process](oncotarget-07-13754-g001){#F1}

###### Main characteristics of the studies on the GGN repeats included in the meta-analysis

  Author (year)          Country   Ethnicity   Method     Control source   Latitude        Case size   Cases/ Controls   Group           Case   Control         
  ---------------------- --------- ----------- ---------- ---------------- --------------- ----------- ----------------- --------------- ------ --------- ----- -----
  Grassetti D (2015)     Italy     Caucasian   Sequence   HB               Mid-latitude    \> 200      302/322           Total           182    120       206   116
                                                                                                       166               Seminomas       97     69              
                                                                                                       136               Non-seminomas   85     51              
  Kristiansen W (2012)   Norway    Caucasian   Sequence   PB               High-latitude   \> 200      635/292           Total           391    244       196   96
                                                                                                       315               Seminomas       191    124             
                                                                                                       320               Non-seminomas   200    120             
  Vastermark A (2011a)   Sweden    Caucasian   Sequence   PB               High-latitude   \> 200      267/214           Total           175    92        141   73
  Vastermark A (2011b)   Denmark   Caucasian   Sequence   PB               High-latitude   \< 200      74/214            Total           43     31        141   73
                                                                                                       158               Seminomas       101    57              
                                                                                                       178               Non-seminomas   114    64              
  Biggs ML (2008)        USA       Mixed       Sequence   PB               Mid-latitude    \> 200      235/576           Total           133    102       359   217
  Garolla A (2005)       Italy     Caucasian   Sequence   PB               Mid-latitude    \< 200      123/115           Total           69     54        71    44

Abbreviations: HB, hospital-based; PB, population-based.

###### Main characteristics of the studies on the CAG repeats included in the meta-analysis

  Author (year)               Country   Ethnicity   Method     Control source   Latitude        Case size   Cases/controls   Group           Case   Control                   
  --------------------------- --------- ----------- ---------- ---------------- --------------- ----------- ---------------- --------------- ------ --------- ---- ---- ----- ----
  Grassetti D (2015)          Italy     Caucasian   Sequence   HB               Mid-latitude    \> 200      302/322          Total           83     171       48   74   211   37
  Kristiansen W (2012)        Norway    Caucasian   Sequence   PB               High-latitude   \> 200      635/304          Total           189    374       72   91   174   72
                                                                                                            316              Seminomas       92     187       37              
                                                                                                            319              Non-seminomas   97     187       35              
  Vastermark A (2011a)        Sweden    Caucasian   Sequence   PB               High-latitude   \> 200      275/214          Total           89     161       25   72   112   30
  Vastermark A (2011b)        Denmark   Caucasian   Sequence   PB               High-latitude   \< 200      89/214           Total           31     52        6    72   112   30
                                                                                                            172              Seminomas       59     97        16              
                                                                                                            186              Non-seminomas   60     111       15              
  Garolla A (2005)            Italy     Caucasian   Sequence   PB               Mid-latitude    \< 200      123/115          Total           38     67        18   37   68    10
  Giwercman A (2004)          Sweden    Caucasian   Sequence   PB               High-latitude   \< 200      83/220           Total           28     41        14   78   99    43
                                                                                                            27               Seminomas       8      19        0               
                                                                                                            41               Non-seminomas   15     18        8               
  Rajpert-De Meyts E (2002)   Denmark   Caucasian   Sequence   HB               High-latitude   \< 200      102/110          Total           32     61        9    43   55    12

Abbreviations: HB, hospital-based; PB, population-based.

For the GGN repeats, seven studies involving 1636 cases (range of 74--635, average of 272.67 ± 180.5) and 1519 controls (range of 115--576, average of 304 ± 154) were included in the meta-analysis.

For the CAG repeats, 6 studies involving 1609 cases (range of 83--635, average of 230 ± 185) and 1285 controls (range of 110--322, average of 214 ± 82.1) met the inclusion criteria and were selected for the meta-analysis.

Association between GGN repeat length and the risk of TC {#s2_2}
--------------------------------------------------------

The association between GGN repeats and the risk of TC is summarized in Figure [2](#F2){ref-type="fig"} and Table [3](#T3){ref-type="table"}. The overall analysis indicated a significant association between GGN repeats and TC \[odds ratio (OR) = 1.22, 95% confidence interval (CI) = 1.05--1.41, *P* = 0.010\]. To clarify the potential effect of latitude, sample size, and histological differences, a subgroup analysis of study populations was also conducted, and a significant association was found between GGN repeats and TC in studies with a sample size \> 200 and in the mid-latitude and seminoma subgroups (for \> 23 *vs.* ≤ 23: OR = 1.23, 95% CI = 1.00--1.51, *P* = 0.050; for \> 23 *vs.* ≤ 23: OR = 1.20, 95% CI = 1.02--1.41, *P* = 0.028; for \> 23 *vs.* ≤ 23: OR = 1.24, 95% CI = 1.00--1.54, *P* = 0.050).

![Forest plot of the GGN repeat polymorphism and the risk of testicular cancer\
(**A**) Overall analysis. (**B**) Case size subgroup. (**C**) Latitude subgroup. (**D**) Histology subgroup. Studies are plotted according to the last name of the first author, followed by the publication year in parentheses. Each square represents the OR point estimate and its size is proportional to the weight of the study. The diamond (and broken line) represents the overall summary estimate and its width indicates the confidence interval. The unbroken vertical line is at the null value (OR = 1.0).](oncotarget-07-13754-g002){#F2}

###### Main results for the GGN repeats included in the meta-analysis

                  Cases/Controls   OR (95% CI)             *P*         *P*~h~   *I*^2^   *Z*    *P*~b~
  --------------- ---------------- ----------------------- ----------- -------- -------- ------ --------
  Overall         1636/1519        **1.22 (1.05--1.41)**   **0.010**   0.929    0.0%     2.59   0.840
  **Case size**                                                                                 
  \> 200          1439/1190        **1.20 (1.02--1.41)**   **0.028**   0.788    0.0%     2.19   
  \< 200          197/329          1.32 (0.91--1.92)       0.143       0.798    0.0%     1.46   
  **Latitude**                                                                                  
  Mid-latitude    660/1013         **1.23 (1.00--1.51)**   **0.050**   0.934    0.0%     1.96   
  High-latitude   976/506          1.20 (0.97--1.49)       0.089       0.549    0.0%     1.7    
  **Histology**                                                                                 
  Seminomas       639/828          **1.24 (1.00--1.54)**   **0.050**   0.776    0.0%     1.96   
  Non-seminomas   634/828          1.14 (0.91--1.42)       0.249       0.845    0.0%     1.15   

Note: *P*~h~ value of the *Q*-test for the heterogeneity test; *P*~b~ value of Egger\'s test for publication bias.

*I*^2^: 0--25, absence of heterogeneity; 25--50, modest heterogeneity; 50, high heterogeneity.

Bold numbers indicate significant differences.

Association between CAG repeat length and the risk of TC {#s2_3}
--------------------------------------------------------

The association between CAG repeat in *AR* and the risk of TC is summarized in Figures [3](#F3){ref-type="fig"} and [4](#F4){ref-type="fig"} and in Table [4](#T4){ref-type="table"}. In brief, the overall analysis indicated no significant association between CAG repeats and the risk of TC for the models evaluated; however, in the subgroup analysis based on latitude, sample size, control source, and histology, significant associations were found between CAG repeats and TC in the population-based (PB) subgroup (for \< 21 + \> 25 *vs.* 21--25: OR = 0.81, 95% CI = 0.68--0.96, *P* = 0.017), mid-latitude subgroup (for \> 25 *vs.* 21--25: OR = 1.65, 95% CI = 1.09--2.50, *P* = 0.017; for \< 21 + \> 25 *vs.* 21--25: OR = 1.38, 95% CI = 1.05--1.82, *P* = 0.021), high-latitude subgroup (for \> 25 *vs.* 21--25: OR = 0.54, 95% CI = 0.41--0.70, *P* = 0.000; for \< 21 + \> 25 *vs.* 21--25: OR = 0.76, 95% CI= 0.64--0.90, *P* = 0.002), seminoma subgroup (for \> 25 *vs.* 21--25: OR = 0.47, 95% CI = 0.33--0.68, *P* = 0.000; for \< 21 + \> 25 *vs.* 21--25: OR = 0.73, 95% CI = 0.57--0.92, *P* = 0.008), and non-seminoma subgroup (for \> 25 *vs.* 21--25: OR = 0.52, 95% CI = 0.37--0.74, *P* = 0.000; for \< 21 + \> 25 *vs.* 21--25: OR = 0.78, 95% CI = 0.62--0.98, *P* = 0.032).

![Forest plot of the long CAG repeat polymorphism and the risk of TC in the subgroup analysis\
(**A**) Latitude subgroup. (**B**) Histology subgroup. Studies are plotted according to the last name of the first author, followed by the publication year in parentheses. Each square represents the OR point estimate and its size is proportional to the weight of the study. The diamond (and broken line) represents the overall summary estimate and its width indicates the confidence interval. The unbroken vertical line is at the null value (OR = 1.0).](oncotarget-07-13754-g003){#F3}

![Forest plot of the abnormal CAG repeat polymorphism and the risk of testicular cancer in the subgroup analysis\
(**A**). Control source subgroup. (**B**). Latitude subgroup. (**C**). Histology subgroup. (**D**). Case size subgroup. Studies are plotted according to the last name of the first author, followed by the publication year in parentheses. Each square represents the OR point estimate and its size is proportional to the weight of the study. The diamond (and broken line) represents the overall summary estimate and its width indicates the confidence interval. The unbroken vertical line is at the null value (OR = 1.0).](oncotarget-07-13754-g004){#F4}

###### Main results for the CAG repeats included in the meta-analysis

  Cases/Controls       \< 21 *vs*. 21--25   \> 25 *vs*. 21--25   \< 21 + \> 25 *vs*. 21--25                                                                                                                                                        
  -------------------- -------------------- -------------------- ---------------------------- ------- ------- ------ ------- ----------------------- ------- ------- ------- ------ ------- ----------------------- ------- ------- ------- ------ -------
  Overall              1609/1285            0.98 (0.83--1.15)    0.809                        0.469   0.0%    0.24   0.371   0.78 (0.49--1.25)       0.304   0.001   73.4%   1.03   0.671   0.90 (0.71--1.14)       0.381   0.031   56.6%   0.88   0.941
  **Control source**                                                                                                                                                                                                                               
  HB                   404/432              1.00 (0.49--2.02)    0.999                        0.041   76.1%   0.00           1.15 (0.50--2.61)       0.741   0.108   61.3%   0.33           1.02 (0.48--2.17)       0.955   0.017   82.5%   0.06   
  PB                   1205/853             0.93 (0.77--1.13)    0.467                        0.980   0.0%    0.73           0.66 (0.42--1.04)       0.071   0.049   58.1%   1.81           **0.81 (0.68--0.96)**   0.017   0.591   0.0%    2.39   
  **Case size**                                                                                                                                                                                                                                    
  \> 200               1212/626             1.04 (0.85--1.28)    0.687                        0.185   40.7%   0.40           0.75 (0.34--1.65)       0.481   0.000   88.0%   0.71           0.94 (0.62--1.44)       0.786   0.004   81.8%   0.27   
  \< 200               397/659              0.87 (0.66--1.15)    0.335                        0.752   0.0%    0.96           0.82 (0.55--1.23)       0.340   0.141   45.0%   0.95           0.86 (0.66--1.11)       0.244   0.453   0.0%    1.16   
  **Latitude**                                                                                                                                                                                                                                     
  Mid-latitude         425/437              1.27 (0.93--1.73)    0.132                        0.411   0.0%    1.51           **1.65 (1.09--2.50)**   0.017   0.789   0.0%    2.39           **1.38 (1.05--1.82)**   0.021   0.549   0.0%    2.31   
  High-latitude        1085/848             0.89 (0.73--1.08)    0.220                        0.873   0.0%    1.23           **0.54 (0.41--0.70)**   0.000   0.698   0.0%    4.62           **0.76 (0.64--0.90)**   0.002   0.983   0.0%    3.11   
  **Histology**                                                                                                                                                                                                                                    
  Seminomas            515/738              0.89 (0.69--1.16)    0.396                        0.481   0.0%    0.85   0.182   **0.47 (0.33--0.68)**   0.000   0.314   13.6%   4.06           **0.73 (0.57--0.92)**   0.008   0.181   41.5%   2.66   
  Non-seminomas        546/738              0.94 (0.73--1.22)    0.652                        0.802   0.0%    0.45   0.870   **0.52 (0.37--0.74)**   0.000   0.285   20.3%   3.65           **0.78 (0.62--0.98)**   0.032   0.657   0.0%    2.14   

Abbreviations: HB, hospital-based; PB, population-based.

Note: *P*~h~ value of *Q*-test for heterogeneity test; *P~b~* value of egger\'s test for publication bias.

*I*^2^: 0--25, absence of heterogeneity; 25--50, modest heterogeneity; 50, high heterogeneity.

Bold numbers indicate significant differences.

Publication bias and small-study effects {#s2_4}
----------------------------------------

To assess the publication bias of the studies, Begg\'s funnel plot and Egger\'s test were performed. The shapes of the funnel plots revealed no evidence of obvious asymmetry. Egger\'s test was used to provide statistical evidence of funnel plot symmetry ([Supplementary Figure S1](#SD1){ref-type="supplementary-material"}) and indicated no evidence of publication bias or small-study effects across the studies (for GGN repeats \> 23 *vs.* ≤ 23, *P* = 0.840; for CAG repeat \< 21 *vs.* 21--25, *P* = 0.371; for CAG repeats \> 25 *vs.* 21--25, *P* = 0.671; for CAG repeats \< 21 + \> 25 *vs.* 21--25, *P* = 0.941).

Sensitivity analysis {#s2_5}
--------------------

To confirm the results of the current study, the *I*^2^ statistics calculated for the overall analysis of the CAG repeats \> 25 *vs.* 21--25 and CAG repeats \< 21 + \> 25 *vs.* 21--25 were 73.4% and 56.6%, respectively, indicating that more than 50% of the abnormal CAG repeats may be due to between-study heterogeneity. We then evaluated the source of heterogeneity in these comparisons by sample size, latitude, and histology stratifications, and we observed no heterogeneity in latitude and histology stratifications (Figure [4](#F4){ref-type="fig"}). Sensitivity analyses were conducted to determine whether modifications in the inclusion criteria of the meta-analysis affected the results. Our results indicated that the studies by Grassetti *et al.* \[[@R10]\] and Garolla *et al.* \[[@R17]\] caused this heterogeneity.

DISCUSSION {#s3}
==========

The present meta-analysis, including 3255 TC cases and 2804 controls from seven case-control studies, explored the association between GGN and CAG repeat polymorphisms in *AR* and the risk of TC. Our results indicated that long GGN repeats were associated with an increased risk of TC, compared with repeats \< 23; similarly, sample size \> 200 and the mid-latitude and seminoma subgroups were associated with an increased risk of TC. In contrast, *AR* CAG repeat polymorphism with \> 25 and \< 21 + \> 25 repeats may confer a protective effect to the TC patients in the analysis of the PB, high-latitude, seminoma, and non-seminoma subgroups. However, *AR* CAG repeat polymorphism with \> 25 and \< 21 + \> 25 repeats in the mid-latitude subgroup were associated with an increased risk of TC.

TC is a very common disease and its incidence has increased worldwide in recent decades. TGCT makes up 95% of all TCs and is the most common solid tumor in men aged 15--39 years \[[@R2], [@R10]\]. Although there has been enormous progress in the clinical treatment of TC and preservation of fertility through sperm banks in recent years, the main causes of the disease remain unclear. However, important risk factors include work, lifestyle, diet, familial history, environmental conditions, and genetic susceptibility \[[@R18]--[@R20]\]. The development of TC is postulated to be due to endocrine disruption, particularly abnormalities in the action of gonadotropins and steroidal sex hormones \[[@R17]\]. Men with androgen insensitivity syndrome caused by *AR* gene mutations have a higher risk of developing TC. There is evidence of an inverse correlation between the variability in *AR* CAG and GGN repeat numbers and the transactivation efficiency in *AR* \[[@R6], [@R9], [@R10], [@R15]\]. Irvine *et al.* \[[@R21]\] suggested that a longer CAG and GGN repeat region might reduce the transactivation activity in *AR*.

Abnormalities in *AR* genes are also common in other disorders, such as prostate cancer, hypospadias, cryptorchidism, and infertility \[[@R22]--[@R25]\]. Many authors have attempted to understand whether reduced androgen sensitivity is caused by point mutations or by excessively long CAG and GGN repeat segments, which might lead to the development of testicular agenesis and consequently increase susceptibility to TC \[[@R10], [@R26]\].

Giwercman *et al.* \[[@R13]\] and Rajpert-De Meyts *et al.* \[[@R12]\] investigated the correlation between CAG and GGN repeats and TC. No statistically significant differences in CAG or GGN repeat numbers were observed between patients with TGCT and the control group. This was the first study that demonstrated a correlation between *AR* CAG repeats, TGCT histology, and disease progression, albeit the study size was limited \[[@R12], [@R13]\]. Grassetti *et al.* \[[@R10]\] observed that there was a larger variability of CAG than GGN repeats in both patients and controls, especially among those with rare alleles. When stratified, men with CAG repeats \< 21 or \> 24 were found to have a 50% and 76% higher risk of TC, respectively, than those with CAG 21--24. Therefore, the risk of developing TC seems to be lower for men with a CAG repeat number between 21 and 24.

In the meta-analysis, our first finding was that long GGN repeats were associated with an increased risk of TC, compared with repeats \> 23; similarly, an increased risk was observed in studies with sample size \> 200 and in the mid-latitude and seminoma subgroups. We speculated that GGN \> 23 was associated with lower *AR* activity compared with the more common genotype with GGN ≤ 23, indicating that low androgen response could play a role in disease progression, which is consistent with the results of previous studies \[[@R10], [@R17]\].

Overall, the present meta-analysis reports for the first time the association between *AR* CAG and GGN repeat polymorphisms and the risk of TC. No significant association was observed between CAG repeat and TC in the models evaluated in the overall analysis, and the groups were heterogeneous. We then evaluated the source of heterogeneity in these groups. Furthermore, in the subgroup analysis of latitude, case size, control source, and histology, a significant association was found between CAG repeats and TC in the PB, mid-latitude, high-latitude, seminoma, and non-seminoma subgroups.

Interestingly, we observed no heterogeneity after stratifying according to latitude and histology. We found that CAG repeat polymorphisms with \> 25 and \< 21 + \> 25 repeats were associated with an increased risk of TC in the mid-latitude subgroup but were associated with a decreased risk of TC in the high-latitude subgroup, indicating that latitude plays a key role in the effect of CAG polymorphism on the risk of TC. In addition, long CAG repeats reduced *AR* activity and increased the risk of TC in the mild mid-latitude environment. Previous studies have indicated that men with CAG repeats \> 25 have lower androgen sensitivity \[[@R27], [@R28]\]. However, in the harsh and cold, high-altitude environment, long CAG repeats may protect against TC. This is because the exposure to different environments or lifestyle-related factors may have opposing effects on the male reproductive system \[[@R29]\].

In addition, we cannot exclude the possibility of the moderate effect of CAG repeat polymorphisms on the risk of TC due to marginal associations. These polymorphisms within or near the *AR* may drive malignant phenotypes. Therefore, large studies focusing on both gene-gene and gene-environment interactions are needed to explore the mechanism of testicular carcinogenesis.

However, this meta-analysis has some limitations. First, some studies with small sample size may not have enough statistical power to determine the real association and are thought to be more likely to report larger beneficial effects compared with larger trials \[[@R30]\]. Second, our results were only based on a Caucasian sample and polymerase chain reaction (PCR) sequences, and a more precise analysis would be conducted if more data were available. Third, clinical disorders are not the result of the disruption of a single gene, and genetic disruptions are embedded within the entire genome and are affected by environment exposure. In fact, other genes related to TC can also play a preeminent role in testis development.

In conclusion, we found that long GGN repeats were associated with an increased risk of TC compared with a reference group. Furthermore, an association between GGN repeats in *AR* and the risk of TC was found in studies with a sample size \> 200 and in the mid-latitude and seminoma subgroups. We found that CAG repeat polymorphisms with \> 25 and \< 21 + \> 25 repeats might confer a protective effect to the patients with TC in the PB, high-latitude, seminoma, and non-seminoma subgroups. However, it CAG repeat polymorphisms with \> 25 and \< 21 + \> 25 repeats in the mid-latitude subgroup were associated with an increased risk of TC.

MATERIALS AND METHODS {#s4}
=====================

Literature selection {#s4_1}
--------------------

Data from single reports were extracted (Figure [1](#F1){ref-type="fig"}). We searched PubMed and Web of Science until July 2015 to identify publications on the association between TC and CAG and/or GGN trinucleotide repeat lengths in *AR*. We focused on the studies performed in humans and on those that utilized the following key words: testicular cancer or TC, androgen receptor or AR, combined with CAG and/or GGN.

The inclusion criteria were as follows: (1) studies that evaluated the association between *AR* CAG or GGC/GGN repeat polymorphisms and the risk of TC; (2) studies with a case-control design; (3) studies that provided sufficient information on CAG or GGC/GGN repeat distributions between patients and controls; (4) studies for which the full text was available. Two reviewers assessed the full text of eligible studies from the above databases. Additional studies were identified by manually searching references of original and review articles on this topic.

Data extraction and verification {#s4_2}
--------------------------------

Information on the enrolled studies is shown in Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}, including: (I) the first author\'s name; (II) year of publication; (III) country or region of origin, ethnicity, and method; (IV) number of cases and controls. Two authors (WJ Jiang and SM Liu) of the study extracted the information independently and screened the citations that met the inclusion criteria. The discrepancies were adjudicated via discussions until a consensus was reached.

Data and statistical analysis {#s4_3}
-----------------------------

Data were divided into three categories: CAG repeat length of 21--25, which was used as the reference group, CAG length \< 21, and CAG length \> 25. The GGN repeat length was divided into 2 categories: GGN repeat length ≤ 23, which was used as the reference group, and GGN length \> 23. To obtain specific data from these categories, we thoroughly analyzed and carefully obtained information from all the studies that met the inclusion criteria.

We predicted the contribution of *AR* CAG and GGN repeat polymorphisms to the risk of TC using the Stata software version 11.0. The OR with 95% (CI) was calculated to measure the strength of the associations \[[@R31]\]. A test of heterogeneity of the pooled results was performed using Cochran\'s *Q* test and Higgins I^2^ statistic \[[@R32]\]. *I*^2^ \> 50% is considered as a measure of significant heterogeneity. If the result of the *Q* test was *P* \> 0.10, the OR was analyzed using the fixed-effects model (Mantel--Haenszel method). Otherwise, a random-effects model (DerSimonian--Laird method) was used in cases of significant heterogeneity. Sensitivity analysis was performed to estimate the stability of the results by removing each study from the analysis, one at a time. Publication bias was evaluated using Begg\'s funnel plot. In addition to the visual inspection of the funnel plot, a value of *P* \< 0.05 was considered to indicate the presence of significant publication bias \[[@R33]--[@R37]\].

SUPPLEMENTARY MATERIALS FIGURES {#s5}
===============================
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